| scholarly article | Q13442814 |
| P50 | author | Britta Siegmund | Q52911890 |
| P2093 | author name string | Elena Sonnenberg | |
| Rainer Glauben | |||
| Martin Wetzel | |||
| Paolo Mascagni | |||
| P2860 | cites work | Monoclonal Anti–Interleukin 23 Reverses Active Colitis in a T Cell–Mediated Model in Mice | Q22250938 |
| Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice | Q24288997 | ||
| Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin | Q24299103 | ||
| Molecular cloning and expression of an IL-6 signal transducer, gp130 | Q24328945 | ||
| Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 | Q24672849 | ||
| Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells | Q27860460 | ||
| Transforming growth factor-beta induces development of the T(H)17 lineage | Q28237370 | ||
| Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug | Q28282479 | ||
| STAT3 regulates cytokine-mediated generation of inflammatory helper T cells | Q28286840 | ||
| TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells | Q28296956 | ||
| Phenotypic and functional features of human Th17 cells | Q29619323 | ||
| Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid | Q29619479 | ||
| Increased expression of interleukin 17 in inflammatory bowel disease | Q29622829 | ||
| Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b | Q33632244 | ||
| The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines | Q34015778 | ||
| Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells | Q34189120 | ||
| The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo | Q34504770 | ||
| Histone deacetylases and cancer: causes and therapies | Q34570082 | ||
| Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. | Q34837305 | ||
| Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications | Q35734509 | ||
| Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. | Q36014379 | ||
| Immune regulation in the intestine: a balancing act between effector and regulatory T cell responses | Q36024794 | ||
| Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid | Q36303956 | ||
| Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation | Q36563545 | ||
| Type 1 and 2 T helper cell-mediated colitis | Q36629338 | ||
| Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets | Q36889961 | ||
| Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. | Q37039027 | ||
| Contributions of dendritic cells and macrophages to intestinal homeostasis and immune defense | Q38080684 | ||
| Acetylation of Stat1 modulates NF-kappaB activity | Q38315771 | ||
| Clinical aspects of inflammatory bowel disease | Q39956026 | ||
| Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat | Q39988736 | ||
| Soluble receptors for cytokines and growth factors: generation and biological function | Q40656511 | ||
| The nuclear factor interleukin-6 (NF-IL6) and signal transducer and activator of transcription-3 (STAT-3) signalling pathways co-operate to mediate the activation of the hsp90beta gene by interleukin-6 but have opposite effects on its inducibility b | Q42159409 | ||
| Ustekinumab induction and maintenance therapy in refractory Crohn's disease | Q42514321 | ||
| Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo | Q43687301 | ||
| Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression | Q45099932 | ||
| Trichostatin A attenuates airway inflammation in mouse asthma model | Q45222913 | ||
| Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease | Q45841458 | ||
| RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. | Q46257713 | ||
| Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells | Q46490320 | ||
| Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice | Q46808312 | ||
| Deacetylase inhibition promotes the generation and function of regulatory T cells. | Q46961808 | ||
| A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease | Q47839326 | ||
| IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. | Q50885474 | ||
| Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. | Q51887698 | ||
| Blockade of IL-6-signaling inhibits the pathogenesis of CD4+ T cell-mediated lethal graft-versus-host reaction against minor histocompatibility antigen. | Q53273278 | ||
| Reconstitution of Scid mice with CD4+CD25- T cells leads to rapid colitis: an improved model for pharmacologic testing. | Q53594901 | ||
| A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses | Q60035686 | ||
| Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis | Q61633704 | ||
| Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease | Q73105062 | ||
| Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate | Q80201780 | ||
| Histone hyperacetylation is associated with amelioration of experimental colitis in mice | Q83059529 | ||
| Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma | Q87414142 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | interleukins | Q194908 |
| P304 | page(s) | 6142-6151 | |
| P577 | publication date | 2014-01-13 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo | |
| P478 | volume | 289 |
| Q33681862 | A Systems Pharmacology Approach to Determine Active Compounds and Action Mechanisms of Xipayi KuiJie'an enema for Treatment of Ulcerative colitis |
| Q35723859 | Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure |
| Q38749824 | Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy |
| Q38986705 | Epigenetic drug discovery: breaking through the immune barrier |
| Q39456337 | Epigenetic involvement in etiopathogenesis and implications in treatment of systemic lupus erythematous |
| Q28075992 | Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic |
| Q64084368 | HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases |
| Q91187764 | HDAC inhibitors promote intestinal epithelial regeneration via autocrine TGFβ1 signalling in inflammation |
| Q38855904 | Histone deacetylase inhibitor restores surfactant protein-C expression in alveolar-epithelial type II cells and attenuates bleomycin-induced pulmonary fibrosis in vivo. |
| Q38763747 | Histone deacetylase inhibitors as immunomodulators in cancer therapeutics |
| Q64914861 | Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy. |
| Q38935540 | Macrophage polarization in response to epigenetic modifiers during infection and inflammation |
| Q38633209 | Oleate but not stearate induces the regulatory phenotype of myeloid suppressor cells |
| Q92598445 | Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor |
| Q92563215 | Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation |
| Q36756039 | Reciprocal regulation of RORγt acetylation and function by p300 and HDAC1. |
| Q64063293 | Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases |
| Q38264859 | Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases |
| Q57712790 | Targeting transcription factor lysine acetylation in inflammatory airway diseases |
| Q37460436 | The histone deacetylase inhibitor, sodium butyrate, exhibits neuroprotective effects for ischemic stroke in middle-aged female rats. |
| Q35799192 | γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy? |
Search more.